LEADER 04243nam 2201033z- 450 001 9910576878603321 005 20231214133250.0 035 $a(CKB)5720000000008389 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84450 035 $a(EXLCZ)995720000000008389 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRole of MicroRNA in Cancer Development and Treatment 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (280 p.) 311 $a3-0365-3806-2 311 $a3-0365-3805-4 330 $aMany researchers around the world have demonstrated that the expression of miRNAs is dysregulated in different tumors. Such dysregulation is caused by multiple mechanisms, and exposure to different carcinogens causes dysregulated epigenetic changes and defects in the miRNA biogenesis machinery. Cancer cells with abnormal miRNA expression evolve the capability to sustain proliferative signaling, evade growth suppressors, resist cell death, activate invasion and metastasis, and induce angiogenesis. Genome-wide profiling demonstrates that miRNA expression signatures are associated with tumor type, tumor grade and clinical outcomes, so miRNAs could be potential candidates for diagnostic biomarkers, prognostic biomarkers, therapeutic targets and preventive screening programs. Although miRNAs have multiple targets, their function in tumorigenesis is due to their regulation of a few specific targets. After the first detection of altered miRNA in leukemia, microRNAs have been demonstrated to be constantly altered in all cancer. More recently, microRNA has been shown to be altered by exposure to environmental carcinogens, thus driving the whole process of carcinogenesis. Our aim is to provide a rigorous peer review and publish cutting-edge research on the role of microRNA in cancer prevention therapy to educate and inspire the scientific community worldwide. 606 $aMedicine$2bicssc 606 $aPharmacology$2bicssc 610 $abreast cancer 610 $amiRNAs 610 $aliquid biopsy 610 $aangiogenesis 610 $abiomarkers 610 $aearly diagnosis 610 $aair pollution 610 $abiomarker 610 $aexposure 610 $ahuman 610 $alung cancer 610 $amiRNA 610 $acarcinogenesis 610 $amicroRNA 610 $aasbestos exposure 610 $aoral squamous cell carcinoma 610 $adiagnosis 610 $aprognosis 610 $asaliva 610 $aneuroblastoma 610 $aMYCN amplification 610 $ametastases 610 $achemoresistance 610 $apublic health genomics 610 $agenetic polymorphisms 610 $aepigenetic modulations 610 $agenetic and microbiome markers 610 $ahealth technology assessment 610 $aearly disease prevention 610 $anonsmokers lung cancer 610 $aenvironmental risk factors 610 $aoncogenes 610 $amutations 610 $aglioblastoma 610 $amicroRNAs 610 $acancer 610 $aqPCR 610 $acancer stem cells 610 $aplasticizers 610 $ain vitro study 610 $aPRISMA 610 $ano-smokers lung cancer 610 $aDNA adducts 610 $amesothelioma 610 $aextracellular vesicles 610 $amiR-625 610 $afluoro-edenite 610 $aasbestos 610 $amalignant mesothelioma 610 $acancer prevention 610 $amicrobiota 610 $aepigenetics 610 $aenvironmental pollutants 610 $acutaneous tissues 610 $aozone exposure 615 7$aMedicine 615 7$aPharmacology 700 $aPulliero$b Alessandra$4edt$01326267 702 $aIzzotti$b Alberto$4edt 702 $aPulliero$b Alessandra$4oth 702 $aIzzotti$b Alberto$4oth 906 $aBOOK 912 $a9910576878603321 996 $aRole of MicroRNA in Cancer Development and Treatment$93037235 997 $aUNINA